Serum Thyrotropin and Triiodothyronine Levels in Levothyroxine-treated Patients

• Published in: The journal of clinical endocrinology and metabolism Vol. 108; no. 6; pp. e258 - e266
• Main Authors: Ettleson, Matthew D, Prieto, Wesley H, Russo, Pedro S T, de Sa, Jose, Wan, Wen, Laiteerapong, Neda, Maciel, Rui M B, Bianco, Antonio C
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 01.06.2023
• Subjects: Analysis; Clinical; Cross-Sectional Studies; Humans; Hypothyroidism; Regression analysis; Thyroid Function Tests; Thyroid hormones; Thyroid-stimulating hormone; Thyrotropin; Thyroxine; Triiodothyronine; Brazil; levothyroxine; thyrotropin; hypothyroidism; triiodothyronine
• ISSN: 0021-972X; 1945-7197
• DOI: 10.1210/clinem/dgac725

Abstract Context Small adjustments in levothyroxine (LT4) dose do not appear to provide clinical benefit despite changes in thyrotropin (TSH) levels within the reference range. We hypothesize that the accompanying changes in serum total triiodothyronine (T3) levels do not reflect the magnitude of the changes in serum TSH. Objective This work aims to characterize the relationships of serum free thyroxine (FT4) vs T3, FT4 vs TSH, and FT4 vs the T3/FT4 ratio. Methods This cross-sectional, observational study comprised 9850 participants aged 18 years and older treated with LT4 from a large clinical database from January 1, 2009, to December 31, 2019. Patients had been treated with LT4, subdivided by serum FT4 level. Main outcome measures included model fitting of the relationships between serum FT4 vs TSH, FT4 vs T3, and FT4 vs T3/FT4. Mean and median values of TSH, T3, and T3/FT4 were calculated. Results The relationships T3 vs FT4 and TSH vs FT4 were both complex and best represented by distinct, segmented regression models. Increasing FT4 levels were linearly associated with T3 levels until an inflection point at an FT4 level of 0.7 ng/dL, after which a flattening of the slope was observed following a convex quadratic curve. In contrast, increasing FT4 levels were associated with steep declines in TSH following 2 negative sigmoid curves. The FT4 vs T3/FT4 relationship was fit to an asymptotic regression curve supporting less T4 to T3 activation at higher FT4 levels. Conclusion In LT4-treated patients, the relationships between serum FT4 vs TSH and FT4 vs T3 across a range of FT4 levels are disproportionate. As a result, dose changes in LT4 that robustly modify serum FT4 and TSH values may only minimally affect serum T3 levels and result in no significant clinical benefit.